Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Policymakers
- Remove Public Health Professionals
- Remove Family & Advocates
- Remove Public Officials
- Remove Substance Abuse
- Remove English
- Remove National Survey on Drug Use and Health (NSDUH)
- Remove TIP Series - Treatment Improvement Protocols (TIPS)
- Remove Alcohol
- Remove Heroin
Main page content
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health
Published: September 2017This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
Published: September 2012This report examines trends in illicit substance use from 2010 to 2011 and from 2002 to 2011 among Americans 12 and older, comparing differences by age group and gender. It also discusses disparities in the need for specialized treatment versus those who actually receive it.